Nordic Pharma has acquired Visant Medical through its subsidiary Amring Pharmaceuticals.
With the acquisition, Nordic will launch and commercialize Visant’s FDA-cleared dry eye disease (DED) therapy, the Lacrifill canalicular occlusive device.
“We’re ecstatic Visant Medical selected Nordic Pharma as their partner and for the opportunity to introduce Lacrifill to the ophthalmologists and optometrists treating the over 16 million people diagnosed with DED in the U.S.,” Philip Gioia, president of the U.S. team that will launch Lacrifill, said in a press release. “Lacrifill